Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Immunicum AB (publ) Publishes the Annual Report for 2017

Immunicum AB
Posted on: 03 Apr 18
Press Release

3 April 2018

Immunicum AB (publ) Publishes the Annual Report for 2017

Immunicum AB (publ; IMMU.ST), today announced that its Annual Report for 2017 is now available on the company's website, www.immunicum.com .

The Annual Report will be sent by regular mail to shareholders and other interested parties upon special request. For further information, please contact the company by telephone +46 (0) 31 41 50 52 or e-mail, info@immunicum.com .

This information is information that Immunicum is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 12:00 CEST on 3 April 2018.

For more information, please contact:

Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 76 243 6810
E-mail: info@immunicum.com

Michaela Gertz, CFO, Immunicum
Telephone: +46 70 926 17 75
E-mail:  ir@immunicum.com  

Media Relations

Gretchen Schweitzer and Joanne Tudorica
Trophic Communications
Telephone: +49 172 861 8540
E-mail:  ir@immunicum.com

About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm www.immunicum.com
20180403_Annual Report Announcement PR_ENG_FINAL


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Immunicum AB via GlobeNewswire
HUG#2181322
GlobeNewswire
globenewswire.com

Last updated on: 04/04/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.